Ultime notizie per Vertex (NASDAQ:VERX) Azioni

Vertex

Vertex Inc is a provider of tax technology and services. Its software, content, and services help customers stay in compliance with indirect taxes that occur in taxing jurisdictions all over the world. Vertex provides cloud-based and on-premise solutions to specific industries for every line of tax, including income, sales, consumer use, value-added, and payroll. The company offers solutions such as tax determination, Tax Data Management, document management, and compliance and reporting among others. The company derives revenue from software subscriptions.

Vertex Inc

Northland Capital Markets analyst Ted Jackson downgrades Xos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) from Outperform to Market Perform and lowers the price target from $9 to $5.

News

Downgrades

Price Target

Analyst Ratings

Northland Capital Markets Downgrades Xos to Market Perform, Lowers Price Target to $5

WestPark Capital analyst Paul Rodriguez reiterates CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Hold.

Reiteration

CRWD

WestPark Capital Reiterates Hold on CrowdStrike Holdings

Rosenblatt analyst Barton Crockett maintains Quad/Graphics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QUAD#NYSE">QUAD</a>) with a Buy and raises the price target from $7.7 to $10.3.

QUAD

Rosenblatt Maintains Buy on Quad/Graphics, Raises Price Target to $10.3

"Alarum's fourth quarter 2024 revenues are estimated at $7.5 million ±3% and Adjusted EBITDA for the fourth quarter 2024 is expected to range from $1.3 million to $1.7 million."

Guidance

ALAR

Alarum Technologies Expects Q4 Revenue Of $7.5M ±3% Vs $7.48M Est

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) with a Buy and lowers the price target from $8 to $5.

CARM

HC Wainwright & Co. Maintains Buy on CARISMA Therapeutics, Lowers Price Target to $5

WIIM

ELAB

Elevai Labs shares are trading lower after the company announced a 1-for-200 reverse stock split.

SNOW

Snowflake shares are trading higher after Wedbush upgraded the stock from Neutral to Outperform.

UXIN

Uxin shares are trading higher after the company reported Q2 sales of $70.85 million, up from $48.80 million year-over-year.

Macy's shares are trading lower after the company delayed its Q3 earnings release and conference call, citing an issue related to delivery expenses in one of its accrual accounts, prompting an independent investigation.

BBWI

Bath & Body Works shares are trading higher after the company reported better-than-expected Q3 EPS and sales and raised its 2024 guidance.

Rosenblatt analyst Catharine Trebnick maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and raises the price target from $325 to $385.

Rosenblatt Maintains Buy on CrowdStrike Holdings, Raises Price Target to $385

The study is evaluating the safety, tolerability, efficacy, pharmacokinetics, and biomarkers of orally administered PL8177 in adult patients with active ulcerative colitis.

Biotech

Health Care

General

Palatin Technologies Has Completed Enrollment In Its Phase 2 Study Of PL8177 For Ulcerative Colitis, The Last Patient Visit Is Expected To Occur In Q1 Of 2025, With Topline Data Expected Shortly Thereafter

HC Wainwright &amp; Co. analyst Mitchell Kapoor initiates coverage on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sell rating and announces Price Target of $80.

Initiation

SRPT

HC Wainwright & Co. Initiates Coverage On Sarepta Therapeutics with Sell Rating, Announces Price Target of $80

Cognition Therapeutics, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>), a clinical-stage company developing drugs to treat neurodegenerative disorders, provided an update on a biomarker(1) analysis from the Phase 2 'SHINE' study in mild-to-moderate Alzheimer's disease. This new analysis focused on plasma samples from all participants who entered the study with lower levels of plasma p-tau217(2) . Several blood-based measures of Alzheimer's disease biology were identified that were normalized in CT1812-treated participants compared to the placebo-treated participants. These biomarker changes occurred in concert with a 95% slowing of cognitive decline as measured by ADAS-Cog11 in the same patients. These data provide further evidence that CT1812 may be preserving cognitive function and slowing disease progression by protecting key neurological system. &nbsp;

CGTX

Cognition Therapeutics Announced 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer's Disease Biology

Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.05 by 300 percent. The company reported quarterly sales of $7.194 million which beat the analyst consensus estimate of $7.000 million by 2.77 percent. This is a 6.58 percent increase over sales of $6.750 million the same period last year.

Earnings

Earnings Beats

Alarum Technologies Q3 2024 Adj. EPS $0.20 Beats $0.05 Estimate, Sales $7.194M Beat $7.000M Estimate

BHVN

Biohaven Says In RESILIENT SMA Study, Taldefgrobep Alfa Showed Clinically Meaningful Improvements In Motor Function At All Timepoints On The Motor Function Measurement-32 Scale, But The Treatment Arm Did Not Statistically Separate On The Primary Outcome At Week 48 Compared To The Placebo+Standard Of Care Group

Contracts

SRM Entertainment Announces Order From An Orlando Theme Park For Its Misting Fans; Initial Order Of $820K For US Theme Parks And $85K For International Parks

AVXL

Anavex Life Sciences Announces Acceptance Of Peer-Reviewed Manuscript Titled 'Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial' In A Reference Alzheimer's Disease Journal

Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) shares are trading higher premarket on Monday after the company successfully completed its 56th Electron mission and finalized a&nbsp;$23.9 million&nbsp;award from the U.S. Department of Commerce.
The company deployed five satellites into Low Earth Orbit for French IoT constellation operator Kinéis.
Rocket Lab&#8217;s &#8220;Ice AIS Baby&#8221; mission successfully launched from New Zealand on November 25, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42156903/rocket-lab-successfully-launches-two-missions-in-less-than-24-hours" rel="noreferrer noopener">deploying five satellites into a 643 km orbit.</a>
The company set a record for its fastest turnaround, completing the launch just 21 hours and 55 minutes after another mission in Virginia.
This marks Rocket Lab&#8217;s 14th mission of 2024 and its 56th overall, bringing its total satellites launched to 203.
Rocket Lab founder and CEO Sir Peter Beck said, &#8220;Two successful launches less than 24 hours apart from pads in different hemispheres. That&#8217;s unprecedented capability in the small launch market and one we&#8217;re immensely proud to deliver at Rocket Lab.&#8221;
Kinéis CEO Alexandre Tisserant, added, &#8221;With 15 Kinéis satellites now in orbit, we&#8217;re one step closer to the full deployment of our dedicated IoT constellation for transmitting data in near-real time, anywhere on the globe.&#8221;
Apart from this, in a seperate release, Rocket Lab disclosed that it finalized&nbsp;a $23.9 million award from the U.S. Department of Commerce to expand its compound semiconductor<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42160043/rocket-lab-signs-23-9m-chips-incentives-award-to-boost-semiconductor-manufacturing" rel="noreferrer noopener"> manufacturing in Albuquerque, New Mexico</a>.
These semiconductors are critical for space-grade solar cells and optoelectronic products essential to national security and commercial applications.
This month, the company also announced a multi-launch agreement with a confidential customer and was awarded a&nbsp;defense contract <a target="_blank" href="https://www.benzinga.com/news/contracts/24/11/41941068/rocket-lab-stock-is-blasting-off-wednesday-whats-going-on" rel="noreferrer noopener">worth up to $8 million</a>.
Investors can gain exposure to the stock via&nbsp;Procure Space ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFO#NASDAQ">UFO</a>) and&nbsp;SPDR S&amp;P Kensho Final Frontiers ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROKT#NYSE">ROKT</a>).
Price Action: RKLB shares are up 7.7% at $25.05 premarket at the last check Monday.
Photo via Company
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin" target="_blank" rel="noreferrer noopener">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Equities

Mid Cap

Movers

RKLB

ROKT

Why Is Rocket Lab USA Stock Surging Today?

Intellia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to nexiguran ziclumeran (nex-z, also known as NTLA-2001) for the treatment of hereditary transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN). Nex-z is an in vivo&nbsp;CRISPR-based investigational&nbsp;therapy designed as a single-dose treatment to inactivate the&nbsp;TTR&nbsp;gene and thereby prevent the production of TTR protein for the treatment of ATTR amyloidosis. Development and commercialization of nex-z is led by Intellia as part of a multi-target collaboration with Regeneron.
"This RMAT designation underscores the transformative potential of nex-z, our investigational in vivo CRISPR-based gene editing therapy for those living with hereditary ATTR amyloidosis with polyneuropathy," said Intellia President and Chief Executive Officer John Leonard, M.D. "It was granted following the FDA's review of our compelling interim Phase 1 data that indicated our one-time treatment led to rapid, deep and durable TTR reduction, which is expected to halt and potentially reverse the disease. We look forward to working closely with the FDA to bring this potential paradigm-shifting therapy to patients as quickly as possible."
The RMAT designation was established under the 21st Century Cures Act to expedite the development and review of promising therapeutic candidates, including genetic therapies, that are intended to treat, modify, reverse or cure a serious or life-threatening disease. RMAT designation includes benefits, such as early interactions with the FDA, including discussions on surrogate or intermediate endpoints that could potentially support accelerated approval and satisfy post-approval requirements, and potential priority review of a product's biologics license application (BLA).
This RMAT designation is the third special regulatory designation received by Intellia for nex-z. Nex-z was also granted Orphan Drug Designation by the U.S. FDA and European Union Orphan Drug Designation by the European Commission.
About nexiguran ziclumeran (nex-z, also known as NTLA-2001) Based on Nobel Prize-winning CRISPR/Cas9 technology, nex-z has the potential to become the first one-time treatment for transthyretin (ATTR) amyloidosis. Nex-z is designed to inactivate the&nbsp;TTR&nbsp;gene that encodes for the transthyretin (TTR) protein. Interim Phase 1 clinical data showed the administration of nex-z led to consistent, deep and long-lasting TTR reduction. Intellia leads development and commercialization of nex-z as part of a multi-target discovery, development and commercialization&nbsp;collaboration&nbsp;with Regeneron.

Government

Regulations

NTLA

Intellia's Single-Dose Gene Editing Treatment for ATTR Amyloidosis Gets FDA Fast-Track Approval Boost

Vertex, Inc. ( ($VERX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex, Inc. presented to its investors. Vertex, Inc....

Vertex, Inc. Achieves Robust Q3 Growth

In a report released today, Patrick Walravens from JMP Securities maintained a Buy rating on Vertex (VERX – Research Report), with a price target o...

JMP Securities Reaffirms Their Buy Rating on Vertex (VERX)

Stifel raised the firm's price target on Vertex (VERX) to $52 from $41 and keeps a Buy rating on the shares following what the firm calls "strong 3...

Vertex price target raised to $52 from $41 at Stifel

JMP Securities raised the firm's price target on Vertex (VERX) to $61 from $47 and keeps an Outperform rating on the shares. The company reported s...

Vertex price target raised to $61 from $47 at JMP Securities

Vertex (VERX – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Chris Quintero from Morgan St...

Vertex's Growth Potential and Raised Price Target Amidst ERP Supercycle and E-Invoicing Expansion

Morgan Stanley analyst Chris Quintero raised the firm's price target on Vertex (VERX) to $62 from $50 and keeps an Overweight rating on the shares....

Vertex price target raised to $62 from $50 at Morgan Stanley

Robert Oliver, an analyst from Robert W. Baird, has initiated a new Buy rating on Vertex (VERX). Robert Oliver has given his Buy rating due to a co...

Vertex: Strong Market Position and Financial Performance Justify Buy Rating Despite Valuation Concerns

William Blair analyst Jake Roberge has maintained their bullish stance on VERX stock, giving a Buy rating on November 15. Jake Roberge has given hi...

Vertex Positioned for Significant Growth Amid ERP Transition: Analyst Recommends Buy

Trump Media saw the largest increase in short interest in October

Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Wix (WIX – Research Report), Accenture (ACN – Rese...

Analysts Offer Insights on Technology Companies: Wix (WIX), Accenture (ACN) and Vertex (VERX)

AMKR

AMTM

BIRK

CART

CELH

CORT

DOCU

ENPH

ENSG

FOUR

LCID

LINE

MDGL

NTRA

ODFL

OLLI

RIVN

SIRI

SMMT

SWKS

UPST

VERX

VRNS

Press Releases

Vertex Acquires ecosio To Accelerate Global E-Invoicing Compliance

Vertex Completes Acquisition of ecosio

Vertex to Present at Goldman Sachs Conference

Vertex Wins the 2024 Oracle Best in Class and North American Partner Awards for Innovation

Vertex Launches Vertex for Salesforce Revenue Cloud

Vertex Earns HDI Certification for Six Years Running, Leading in Tax Technology Customer Support

Vertex to Announce Third Quarter 2024 Financial Results on Wednesday, November 6, 2024

Vertex Advances Tax Technology Innovation at Exchange 2024

Vertex Announces Third Quarter 2024 Financial Results

Vertex Global Survey Finds Half of Organizations Lagging in Tax and Finance Automation

Comments

Vertex

Notizie

Ultime notizie per Vertex (NASDAQ:VERX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO